Performance Characteristics of Different Anti-Double-Stranded DNA Antibody Assays in the Monitoring of Systemic Lupus Erythematosus

Objective. We sought to evaluate different anti-double-stranded DNA assays for their performance characteristics in monitoring disease activity fluctuations in systemic lupus erythematosus (SLE). Methods. 36 active SLE patients were followed monthly. At each study visit (total n=371), blood was coll...

Full description

Saved in:
Bibliographic Details
Published in:Journal of immunology research 2017-01, Vol.2017 (2017), p.1-5
Main Authors: Dervieux, Thierry, Conklin, John, Ibarra, Claudia, O’Malley, Tyler, Bentow, C., Mahler, Michael, Aure, Mary Ann R.
Format: Article
Language:English
Subjects:
Anti-DNA antibodies
Antibodies, Antinuclear - blood
Antibody Affinity
Arthritis
Assaying
Autoimmune diseases
Avidity
Computer Simulation
Crithidia luciliae
Deoxyribonucleic acid
Disease
Disease Progression
DNA
DNA - immunology
Fluctuations
Health risk assessment
Humans
Immunoassay
Immunoassay - instrumentation
Immunoassay - methods
Immunoglobulins
Immunology
Lupus
Lupus Erythematosus, Systemic - diagnosis
Monitoring, Physiologic
Performance evaluation
Rheumatism
Rheumatology
Severity of Illness Index
Systemic lupus erythematosus
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Objective. We sought to evaluate different anti-double-stranded DNA assays for their performance characteristics in monitoring disease activity fluctuations in systemic lupus erythematosus (SLE). Methods. 36 active SLE patients were followed monthly. At each study visit (total n=371), blood was collected and disease activity was scored using the SELENA-SLEDAI (excluding anti-dsDNA or complement components) and by a physician’s global assessment (PGA). Four anti-dsDNA tests were compared. Linear mixed-effects models with random intercept and fixed slopes were used to evaluate the relationship between the longitudinal fluctuations of disease activity and anti-dsDNA titers. Results. At enrollment, positivity for QUANTA Lite and high-avidity anti-dsDNA assay was both 64% and significantly lower than anti-dsDNA positivity by QUANTA Flash (83%) and CLIFT (96%). Linear mixed-effects modeling indicated that the change in clinical SELENA-SLEDAI scores was associated with the titers of all anti-dsDNA with QUANTA Flash yielding the highest marginal R2 (0.15; p
ISSN:2314-8861
2314-7156
DOI:10.1155/2017/1720902